International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationRadiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial
Introduction
Opinion remains divided on how much androgen suppression (AS) is necessary for men with locally advanced prostate cancer if they are treated with escalated radiation (RT) doses.
In our first report of our RT dose escalation substudy for the RADAR trial, we found that increasing AS and RT dose escalation independently reduced local progressions.1 We had insufficient data at that time, with minimum follow-up of 6.5 years after randomization, to determine whether a reduction in distant progressions and prostate cancer deaths had been achieved by either treatment modality. With minimum follow-up of 10 years, we now have sufficient data to address these outcomes. In this report our aims are (1) to test if longer AS influences distant progression and the other secondary endpoints independently of RT dose, (2) to estimate the effect of AS duration within strata of RT doses, and (3) to assess if there is an independent ordered effect of RT dose on outcomes.
Section snippets
Patients and treatment
Men with histologically confirmed adenocarcinoma of the prostate without lymph node or systemic metastases, and with cT2b-4 stage primary tumors or cT2a stage primary tumors with Gleason score ≥7 and baseline prostate-specific antigen (PSA) levels ≥10 ng/mL, were eligible to participate after providing informed consent. All subjects received the standard treatment of 6 months of leuprorelin (22.5 mg every 3 months, intramuscularly) commencing at randomization, 5 months before RT to the prostate
Results
Of the 1071 trial subjects, 1051 subjects who received radiation therapy as specified in the trial protocol were eligible for inclusion in these analyses. Four out of the 23 participating centers were equipped with HDRB facilities. Median follow-up duration from randomization was 10.5 years (interquartile range, 8.2-11.8 years). Baseline characteristics and RT dose assignment were well balanced between the AS groups (Table 1). There were some imbalances in baseline characteristics according to
Discussion
This study explores the duration of AS in the context of dose-escalated radiation therapy using 10-year data from the RADAR trial for locally advanced, high-risk PC. To our knowledge, RADAR is the first RCT to randomize subjects to short or longer AS after stratifying by radiation dose. Subjects received either 6AS or 18AS in combination with one of 4 RT dosing options: 66 Gy, 70 Gy, 74 Gy, or HDRB. Our study showed no evidence of an interaction between AS duration and RT dose and that
Conclusions
Our study showed that 18 months of AS significantly reduced distant progression compared with 6 months AS independently of RT dose. It also provides the first definitive evidence of the benefit of a longer duration of AS in men treated with EBRT plus HDR boost, confirming that extreme-dose escalated RT does not obviate the need for AS. Based on these findings, 18 months of AS together with EBRT plus HDR boost should be considered an effective option for men with locally advanced, high-risk PC.
References (27)
- et al.
Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial
Radiother Oncol
(2015) - et al.
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
Radiother Oncol
(2012) - et al.
Assuring high quality treatment delivery in clinical trials: Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study
Radiother Oncol
(2009) - et al.
Detailed review and analysis of complex radiotherapy clinical trial planning data: Evaluation and initial experience with the SWAN software system
Radiother Oncol
(2008) - et al.
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): An open-label, randomised, phase 3 factorial trial
Lancet Oncol
(2014) - et al.
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
Lancet Oncol
(2019) - et al.
Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer
Brachytherapy
(2013) - et al.
Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer
Int J Radiat Oncol Biol Phys
(2011) - et al.
Lack of apparent survival benefit with use of androgen deprivation therapy in patients with high-risk prostate cancer receiving combined external beam radiation therapy and brachytherapy
Int J Radiat Oncol Biol Phys
(2018) - et al.
Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs brachytherapy boost for prostate cancer
Brachytherapy
(2019)
Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer
Brachytherapy
Importance of local control in early-stage prostate cancer: Outcomes of patients with positive postradiation therapy biopsy results treated in RTOG 9408
Int J Radiat Oncol Biol Phys
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer
J Urol
Cited by (46)
Can Extreme Dose Escalation With External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients With High-Risk Localized Prostate Cancer?
2024, International Journal of Radiation Oncology Biology PhysicsTrimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)
2024, International Journal of Radiation Oncology Biology PhysicsIs Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial
2024, International Journal of Radiation Oncology Biology PhysicsAn Updated Analysis of the Survival Endpoints of ASCENDE-RT
2023, International Journal of Radiation Oncology Biology Physics
Note—An online CME test for this article can be taken at https://academy.astro.org.
This work was supported by the National Health and Medical Research Council of Australia (Project Application ID 300705, 455521 and 1099149); The Goodfellow Foundation, Auckland (New Zealand); Cancer Standards Institute of New Zealand; Novartis Pharmaceuticals Australia; and AbbVie Pharmaceuticals Australia.
Disclosures: J.W.D. reports grants from Novartis Pharmaceuticals and grants and nonfinancial support from AbbVie during the conduct of the study. All other authors declare no competing interests.